Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Events

27 Aug 2016 - 31 Aug 2016

Mesh Matrix Treats Hard-to-Heal Wounds

By HospiMedica International staff writers
Posted on 27 Feb 2014
Print article
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
A new multilayer matrix device accommodates moderate to heavy wound exudate and provides effective contouring functionality in wound treatment.

The MatriStem Multilayer Wound Matrix device is designed to maintain and support a healing environment through constructive tissue remodeling for both acute and chronic wounds. The device is comprised of naturally occurring urinary bladder matrix (UBM), the basement membrane of porcine urinary bladder tissue, which is disinfected, packaged, and sterilized to produce a non-cross-linked, completely resorbable, acellular extracellular matrix (ECM) scaffold that is rich with naturally occurring collagens and proteins.

UBM provides several distinguishable characteristics, including the recruitment of progenitor cells, chemotactic and mitogenic activities, and site-specific tissue remodeling. UBM also has the ability to facilitate the body’s own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two-year shelf life; and superior ease-of-use characteristics.

MatriStem is easy to prepare, apply, and fixate, and requires no special handling requirements. It is indicated for all types of wound management, including pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological, and gastroenterological anatomy. The MatriStem Multilayer Wound Matrix device is a product of ACell (Columbia, MD, USA), and has been approved by the US Food and Drug Administration (FDA).

“ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management,” said Jim DeFrancesco, CEO of ACell. “The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds.”

Related Links:

ACell



Print article
Fluke Biomedical
JD Honigberg International

Channels

Women's Health

view channel
Image: A new study describes a novel index that quantifies net bone formation and resorption, which may help identify women that experience fast bone loss across the menopause transition (Photo courtesy of UCLA).

Novel Index Could Identify Rapid Bone Loss Risk

Developed by researchers at the University of California, Los Angeles (UCLA; USA), and the University of Tokyo (Japan), the Bone Balance Index (BBI) estimates the relationship between resorption (urinary... Read more

Business

view channel

GE and ThoughtWire Partner to Improve Digital Transformation in Healthcare

GE Healthcare Partners (Little Chalfont, UK) and ThoughtWire (Ontario, Canada) have entered into a five-year collaboration agreement to help hospitals and health systems implement new digital tools for improving their productivity, quality of care and overall patient experience. Both GE Healthcare Partners and the Toronto-based... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.